These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Beta-blockers in portal hypertension: new developments and controversies. Tripathi D; Hayes PC Liver Int; 2014 May; 34(5):655-67. PubMed ID: 24134058 [TBL] [Abstract][Full Text] [Related]
24. Common complications of cirrhosis: do we follow too often the 'Casablanca strategy'? Gundling F; Schmidt T; Schepp W Liver Int; 2011 Nov; 31(10):1598-600. PubMed ID: 21745306 [No Abstract] [Full Text] [Related]
25. β-blockers and refractory ascites in cirrhosis: the message of a team of true scientists. Angeli P J Hepatol; 2011 Oct; 55(4):743-4. PubMed ID: 21396970 [No Abstract] [Full Text] [Related]
26. When should the β-blocker window in cirrhosis close? Ge PS; Runyon BA Gastroenterology; 2014 Jun; 146(7):1597-9. PubMed ID: 24768679 [No Abstract] [Full Text] [Related]
27. Care of the cirrhotic patient. Grewal P; Martin P Clin Liver Dis; 2009 May; 13(2):331-40. PubMed ID: 19442922 [TBL] [Abstract][Full Text] [Related]
28. [Long-term drug treatments to improve prognosis of patients with liver cirrhosis and to prevent complications due to portal hypertension]. Holstege A Z Gastroenterol; 2019 Aug; 57(8):983-996. PubMed ID: 31398770 [TBL] [Abstract][Full Text] [Related]
29. [Antibiotics can ameliorate circulatory complications of liver cirrhosis]. Madsen BS; Schaffalitzky de Muckadell OB Ugeskr Laeger; 2011 Aug; 173(35):2127-30. PubMed ID: 21884664 [TBL] [Abstract][Full Text] [Related]
30. Preventing the development of varices in cirrhosis. Garcia-Tsao G J Clin Gastroenterol; 2007; 41 Suppl 3():S300-4. PubMed ID: 17975480 [TBL] [Abstract][Full Text] [Related]
31. Current status of liver diseases in Korea: liver cirrhosis. Jang JW Korean J Hepatol; 2009 Dec; 15 Suppl 6():S40-9. PubMed ID: 20037279 [TBL] [Abstract][Full Text] [Related]
32. [The effect of portal hypertension on prognosis in patients with decompensated liver cirrhosis]. Zhang JY; Kuai JH; Jia JD; Wang BE; Qin CY Zhonghua Gan Zang Bing Za Zhi; 2009 Apr; 17(4):263-5. PubMed ID: 19403023 [TBL] [Abstract][Full Text] [Related]
33. Reply: To PMID 24631577. Mandorfer M; Peck-Radosavljevic M; Reiberger T Gastroenterology; 2014 Oct; 147(4):942. PubMed ID: 25167985 [No Abstract] [Full Text] [Related]
34. Liver cirrhosis. Pinzani M; Rosselli M; Zuckermann M Best Pract Res Clin Gastroenterol; 2011 Apr; 25(2):281-90. PubMed ID: 21497745 [TBL] [Abstract][Full Text] [Related]
36. Management of ascites in the patient with portal hypertension with emphasis on spontaneous bacterial peritonitis. Navasa M; Rodés J Semin Gastrointest Dis; 1997 Oct; 8(4):200-9. PubMed ID: 9360284 [TBL] [Abstract][Full Text] [Related]
37. Review article: potential mechanisms of action of rifaximin in the management of hepatic encephalopathy and other complications of cirrhosis. Bajaj JS Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():11-26. PubMed ID: 26618922 [TBL] [Abstract][Full Text] [Related]
38. Managing the complications of cirrhosis. Menon KV; Kamath PS Mayo Clin Proc; 2000 May; 75(5):501-9. PubMed ID: 10807079 [TBL] [Abstract][Full Text] [Related]
39. Microbiome and bacterial translocation in cirrhosis. Gómez-Hurtado I; Such J; Francés R Gastroenterol Hepatol; 2016 Dec; 39(10):687-696. PubMed ID: 26775042 [TBL] [Abstract][Full Text] [Related]